Who founded Context Therapeutics?

Context Therapeutics was founded by Martin Albert Lehr, Martin Lehr in 2021.

Who are Context Therapeutics's investors?

Context Therapeutics's investors include Nextech Invest, Torrey Pines Investment.

How much funding has Context Therapeutics raised?

Context Therapeutics has disclosed $100M raised across 1 round.

Where is Context Therapeutics headquartered?

Context Therapeutics is headquartered in Philadelphia, US.

Context Therapeutics

NASDAQ: CNTX

Philadelphia, US · Founded 2021 · Delaware corporation · 2 known investors

Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.

Biotech Healthtech

Founders & leadership

Context Therapeutics was founded in 2021 by Martin Albert Lehr and Martin Lehr.

Martin Albert LehrCo-founder

Martin Lehr inCo-founder · CEO and DirectorMartin Lehr is the founder of Context Therapeutics, a clinical-stage company developing T cell engaging bispecific antibody therapies for solid tumors, with a pipeline targeting antigens including Claudin 6, mesothelin, and Nectin-4.

Jennifer Minai-AzaryExecutive

Alex LevitNamed on SEC filing

Linda Beth WestNamed on SEC filing

Richard Jay BermanNamed on SEC filing

Philip KantoffNamed on SEC filing

Jennifer Evans StaceyNamed on SEC filing

Investors · 2

Nextech InvestZurich · $648K – $3.2M

Torrey Pines InvestmentSan Diego

Reported raises · per SEC filings

Form D private placements

$100M disclosed across 1 round · 2024

▶$100MraisedMay 2024 · 26 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Alex LevitExecutive Officer
Linda Beth WestDirector
Martin Albert LehrExecutive Officer, Director
Richard Jay BermanDirector
Philip KantoffDirector
Jennifer Minai-AzaryExecutive Officer
Jennifer Evans StaceyDirector

Offering amount: $100M
Amount sold: $100M
Sales commissions: $5M
Placement agents: Piper Sandler & Co.
First sale: May 2024
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Kite Pharma37 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.

Power35 shared keywordsPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.

Click Therapeutics34 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.

Solu34 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies competing with Context Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2016	$225.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Context Therapeutics do?: Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Who founded Context Therapeutics?: Context Therapeutics was founded by Martin Albert Lehr, Martin Lehr in 2021.
Who are Context Therapeutics's investors?: Context Therapeutics's investors include Nextech Invest, Torrey Pines Investment.
How much funding has Context Therapeutics raised?: Context Therapeutics has disclosed $100M raised across 1 round.
Where is Context Therapeutics headquartered?: Context Therapeutics is headquartered in Philadelphia, US.